AUTOIMMUNE INFLAMMATORY TWIN

AI-TWIN is a pioneering startup company that focuses on breakthrough discoveries and ambitious objectives in the realms of personalized medicine, biomedical research, and clinical research.

By merging human biology with innovative microfabrication technologies, AI-TWIN is heading towards the era of personalized medicine.

A DIGITAL TWIN FOR PERSONALIZED MEDICINE

AI-TWIN approach involves engineering high-resolution 3D multi-tissues as biological models of individual patients starting from their own biopsies and couple these Biological Twins to their Digital Twins, which are computationally built models.

The use of Digital Twins in healthcare holds immense potential for revolutionizing applied research starting from its pathophysiological modelling to precision medicine, clinical trials, and public health initiatives.

Through its cutting-edge initiatives, AI-TWIN is at the forefront of leveraging advanced technologies to enhance healthcare practices and drive forward personalized treatment approaches.

FUTURE PERSPECTIVES

AI-TWIN is developing OoCs in the form of microfluidic devices for 3D cell cultivation, capable of reproducing the tissue microenvironment thanks to the engineering of geometric, mechanical and biochemical factors and therefore mimicking the structures and functions of human organs in vivo.

By utilizing each patient’s cells and integrating biological twins with digital twins, AI-TWIN enables a personalized medicine approach in treatment discovery and adjustment.

Support preclinical studies using readily available tissue microchips and not animal/in vitro models

Evaluate drug candidates rapidly on a large scale

Obtain a high quantity of real time data

Create a digital twin adaptable to other conditions

INNOVATION

The company’s innovative approach involves creating and validating data from the biological twin/digital twin pairing, which represents the future of the biomedical field and will lead to the development of Clinical Trials on Chips, used in the evaluation of the effectiveness, toxicity and validity of new drugs, carried out in a fast, less expensive and ethical manner (without side effects for patients, or untreated patients when allocated to the placebo arm).

This advancement in drug evaluation processes is set to revolutionize the pharmaceutical industry by providing a platform for conducting patient-specific clinical trials and enhancing drug development strategies.

FOUNDERS

Annalisa Chiocchetti
MD, PhD

Lia Rimondini
MD

Francesca Gervaso
PhD

Alessandro Polini
PhD

ADVISORY BOARD

Roberto Giannantonio – PhD

Corporate R&D Manager at SAES Getters Spa, CEO ETC S.r.L. (ISMN-CNR and University of Bologna), Italy

Federico Alberto Grassi

Director of the Orthopaedics and Traumatology Unit of the San Matteo Polyclinic, Pavia, Italy; full professor of Locomotor System Diseases at the University of Pavia, Italy.

Mauro Grigioni

Director of Bioengineering Research at the Istituto Superiore di Sanità and coordinator of the National Center for Innovative Technologies in Public Health (TISP), Italy.

PARTNERS

AUTOIMMUNE INFLAMMATORY TWIN

AI-TWIN is a pioneering startup company that focuses on breakthrough discoveries and ambitious objectives in the realms of personalized medicine, biomedical research, and clinical research.

By merging human biology with innovative microfabrication technologies, AI-TWIN is heading towards the era of personalized medicine.

A DIGITAL TWIN
FOR PERSONALIZED MEDICINE

AI-TWIN approach involves engineering high-resolution 3D multi-tissues as biological models of individual patients starting from their own biopsies and couple these Biological Twins to their Digital Twins, which are computationally built models.

The use of Digital Twins in healthcare holds immense potential for revolutionizing applied research starting from its pathophysiological modelling to precision medicine, clinical trials, and public health initiatives.

Through its cutting-edge initiatives, AI-TWIN is at the forefront of leveraging advanced technologies to enhance healthcare practices and drive forward personalized treatment approaches.

FUTURE PERSPECTIVES

Our research represents a turning point for clinical practice, the pharmaceutical industry, and academia.

We aim at developing a new generation of in vitro systems, the next-generation personalized organ on chip (OoC).

They are created with the use of a microfluidic device, starting from patient biopsies, useful for advanced research on new treatments and permitting patient-specific clinical trials-on-chip.

 

Support preclinical studies using readily available tissue microchips and not animal/in vitro models

Lowering costs for drug screenings

Translational research to identify new therapeutic markers

Improved patient care
and reduced side effects

INNOVATION

The company’s innovative approach involves creating and validating data from the biological twin/digital twin pairing, which represents the future of the biomedical field and will lead to the development of Clinical Trials on Chips, used in the evaluation of the effectiveness, toxicity and validity of new drugs, carried out in a fast, less expensive and ethical manner (without side effects for patients, or untreated patients when allocated to the placebo arm).

This advancement in drug evaluation processes is set to revolutionize the pharmaceutical industry by providing a platform for conducting patient-specific clinical trials and enhancing drug development strategies.

FOUNDERS

Annalisa Chiocchetti
MD, PhD

Lia Rimondini
MD

Francesca Gervaso
PhD

Alessandro Polini
PhD

ADVISORY BOARD

Roberto Giannantonio – PhD

Corporate R&D Manager at SAES Getters Spa, CEO ETC S.r.L. (ISMN-CNR and University of Bologna), Italy

Federico Alberto Grassi

Director of the Orthopaedics and Traumatology Unit of the San Matteo Polyclinic, Pavia, Italy; full professor of Locomotor System Diseases at the University of Pavia, Italy.

Mauro Grigioni

Director of Bioengineering Research at the Istituto Superiore di Sanità and coordinator of the National Center for Innovative Technologies in Public Health (TISP), Italy.

PARTNERS

Ai-Twin srl

info@aitwin.it

Sede legale e operativa
C.so Trieste, 15/A – 28100 Novara (NO)

C.F./P.IVA 02722210032
SDI SUBM70N

WHERE TO FIND US